Get startedLog in
    Picture of Drugs Made In America Acquisition logo

    DMAA — Drugs Made In America Acquisition Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    FinancialsSpeculativeSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M
    Source:ARS10-K
    Standards:—
    USG
    Status:FinalFinal
    Net Income/Starting Line0-0.28
    Non-Cash Items—0.03
    Other Non-Cash Items
    Changes in Working Capital—0.077
    Change in Accrued Expenses
    Cash from Operating Activities0-0.172
    Financing Cash Flow Items—-0.364
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities—0.174
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash00.001